Background
PsA, musculoskeletal and dermatologic manifestations, Psoriatic arthritis, PsA., PsA disease, enthesitis
PSORIATIC ARTHRITIS, ENTHESITIS, CHRONIC INFLAMMATORY DISEASE
Psoriatic arthritis (PsA) is a chronic inflammatory disease with musculoskeletal and dermatologic manifestations [Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Efficacy and safety of tofacitinib 5 mg twice daily (BID; recommended dosage) [In this post hoc analysis, the effects of tofacitinib on enthesitis, its impact on PsA disease activity, and patient-reported outcomes (PROs) in patients with vs without enthesitis at baseline, were further evaluated. Development of de novo enthesitis was also investigated.